Nodes: 629, Authors: 2813, Journals: 198, Outer References: 19298, Words: 1556
Collection span: 2004 - 2006
View: Overview. Sorted by year, source, volume, issue, page. Page 1 of 7: [  1  2  3  4  5  6  7 ]

#	LCR	NCR	Node / Date / Journal / Author	LCS	GCS
1	3	8	1 2004 AMERICAN FAMILY PHYSICIAN 70 (9): 1637-+ Collins F Genomics and the family physician: Realizing the potential	0	1
2	2	135	2 2004 AMERICAN JOURNAL OF CLINICAL PATHOLOGY 122 (4): 598-609 Ross JS; Schenkein DP; Pietrusko R; Rolfe M; Linette GP; et al. Targeted therapies for cancer 2004	7	30
3	5	39	3 2004 ANNALES DE PATHOLOGIE 24 (5): 416-426 Penault-Llorca F; Sobourin JC The pathologist and EGFR in 2004: I like you, so don't I	0	0
4	2	15	4 2004 ANNALS OF ONCOLOGY 15: 81-83 Giaccone G Twenty-five years of treating advanced NSCLC: what have we achieved?	0	0
5	2	144	5 2004 BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER 1705 (1): 53-66 Cummings J; Ward TH; Ranson M; Dive C Apoptosis pathway-targeted drugs - from the bench to the clinic	1	2
6	2	41	6 2004 BREAST CANCER RESEARCH 6 (5): 204-210 Lin NU; Winer EP New targets for therapy in breast cancer - Small molecule tyrosine kinase inhibitors	1	3
7	3	25	7 2004 BRITISH JOURNAL OF CANCER 91: S1-S2 Camus P Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management - Introduction	0	0
8	1	20	8 2004 BRITISH JOURNAL OF CANCER 91 (3): 430-433 Jacot W; Pujol JL; Boher JM; Lamy PJ Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer	1	3
9	2	44	9 2004 BRITISH JOURNAL OF CANCER 91 (7): 1301-1307 Swinson DEB; Cox G; O'Byrne KJ Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer	3	3
10	1	34	10 2004 BRITISH JOURNAL OF CANCER 91 (12): 2048-2055 Lassus H; Sihto H; Leminen A; Nordling S; Joensuu H; et al. Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma	0	2
#	LCR	NCR	Node / Date / Journal / Author	LCS	GCS
11	1	75	11 2004 BULLETIN DU CANCER 91 (9): 685-694 Monnier L; Milano G; Penault-Llorca F; Merlin JL Targeting of membrane receptor tyrosine kinases: is there resistance in the HER?	1	1
12	1	85	12 2004 CANCER 101 (6): 1428-1436 Chen YC; Chen JH; Richard K; Chen PY; Christiani DC Lung adenocarcinorna and human papillomavirus infection	1	2
13	2	29	13 2004 CANCER 101 (7): 1632-1638 Shah L; Walter KL; Borczuk AC; Kawut SM; Sonett JR; et al. Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma	1	5
14	2	86	14 2004 CANCER 101 (8): 1733-1744 Gridelli C; Massarelli E; Maione P; Rossi A; Herbst RS; et al. Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly	0	1
15	1	51	15 2004 CANCER CELL 5 (6): 525-531 Arteaga CL; Baselga J Tyrosine kinase inhibitors: Why does the current process of clinical development not apply to them?	9	19
16	1	28	16 2004 CANCER CELL 6 (2): 111-116 Dinney CPN; McConkey DJ; Millikan RE; Wu XF; Bar-Eli M; et al. Focus on bladder cancer	0	6
17	2	63	17 2004 CANCER CELL 6 (3): 209-214 Ishizawar R; Parsons SJ c-Src and cooperating partners in human cancer	3	13
18	3	63	18 2004 CANCER CELL 6 (4): 321-326 Abbruzzese JL; Lippman SM The convergence of cancer prevention and therapy in early-phase clinical drug development	1	8
19	4	76	19 2004 CANCER CELL 6 (5): 433-438 Weir B; Zhao XJ; Meyerson M Somatic alterations in the human cancer genome	2	3
20	1	21	20 2004 CANCER RESEARCH 64 (18): 6385-6389 Cools J; Mentens N; Furet P; Fabbro D; Clark JJ; et al. Prediction of resistance to small molecule FLT3 inhibitors: Implications for molecularly targeted therapy of acute leukemia	5	15
#	LCR	NCR	Node / Date / Journal / Author	LCS	GCS
21	2	22	21 2004 CANCER RESEARCH 64 (20): 7241-7244 Tracy S; Mukohara T; Hansen M; Meyerson M; Johnson BE; et al. Gefitinib induces apoptosis in the EGFR(L858R) non-small-cell lung cancer cell line H3255	24	29
22	2	45	22 2004 CANCER RESEARCH 64 (23): 8723-8730 Chen YL; Law PY; Loh HH Inhibition of Akt/protein kinase B signaling by naltrindole in small cell lung cancer cells	0	3
23	2	20	23 2004 CANCER RESEARCH 64 (24): 8816-8820 Bentires-Alj M; Paez JG; David FS; Keilhack H; Halmos B; et al. Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia	1	14
24	3	29	24 2004 CANCER RESEARCH 64 (24): 8919-8923 Kosaka T; Yatabe Y; Endoh H; Kuwano H; Takahashi T; et al. Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications	46	51
25	2	32	25 2004 CANCER RESEARCH 64 (24): 9093-9100 Reyzer ML; Caldwell RL; Dugger TC; Forbes JT; Ritter CA; et al. Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics	1	4
26	3	15	26 2004 CANCER RESEARCH 64 (24): 9101-9104 Arao T; Fukumoto H; Takeda M; Tamura T; Saijo N; et al. Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474	8	10
27	2	38	27 2004 CANCER RESEARCH 64 (24): 9139-9143 Amador ML; Oppenheimer D; Perea S; Maitra A; Cusati G; et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors	9	12
28	1	26	28 2004 CANCER SCIENCE 95 (10): 772-776 Saijo N What are the reasons for negative phase III trials of molecular-target-based drugs?	0	0
29	2	10	29 2004 CELL CYCLE 3 (7): 833-835 Druker BJ Imatinib: Paradigm or anomaly?	4	5
30	3	83	30 2004 CELL CYCLE 3 (8): 1035-1042 Blagosklonny MV Analysis of FDA approved anticancer drugs reveals the future of cancer therapy	2	4
#	LCR	NCR	Node / Date / Journal / Author	LCS	GCS
31	2	32	31 2004 CELL CYCLE 3 (10): 1221-1224 Samuels Y; Velculescu VE Oncogenic mutations of PIK3CA in human cancers	1	8
32	3	8	32 2004 CELL CYCLE 3 (12): 1496-1497 Settleman J Inhibition of mutant EGF receptors by Gefitinib - Targeting an Achilles' heel of lung cancer	2	4
33	1	4	33 2004 CELLULAR AND MOLECULAR LIFE SCIENCES 61 (23): 2895-2896 Gambacorti-Passerini C Oncogenic protein tyrosine kinases	0	2
34	3	24	34 2004 CLINICAL CANCER RESEARCH 10 (19): 6522-6527 Messersmith WA; Laheru DA; Senzer NN; Donehower RC; Grouleff P; et al. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): Early termination due to increased toxicities	2	6
35	1	13	35 2004 CLINICAL CANCER RESEARCH 10 (20): 6759-6763 Simon R; Maitournam A Evaluating the efficiency of targeted designs for randomized clinical trials	3	9
36	1	45	36 2004 CLINICAL CANCER RESEARCH 10 (21): 7112-7120 Calvo E; Tolcher AW; Hammond LA; Patnaik A; de Bono JS; et al. Administration of CI-1033, an irreversible Pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: A phase I pharmacokinetic and food effect study	2	6
37	2	36	37 2004 CLINICAL CANCER RESEARCH 10 (21): 7311-7317 Kim YH; Ishii G; Goto K; Nagai K; Tsuta K; et al. Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung	2	3
38	2	37	38 2004 CLINICAL CANCER RESEARCH 10 (22): 7547-7554 Petty WJ; Dragnev KH; Memoli VA; Ma Y; Desai NB; et al. Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers	2	8
39	2	48	39 2004 CLINICAL CANCER RESEARCH 10 (22): 7764-7774 Kalish LH; Kwong RA; Cole IE; Gallagher RM; Sutherland RL; et al. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines	2	4
40	2	25	40 2004 CLINICAL CANCER RESEARCH 10 (24): 8195-8203 Huang SF; Liu HP; Li LH; Ku YC; Fu YN; et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan	37	39
#	LCR	NCR	Node / Date / Journal / Author	LCS	GCS
41	2	41	41 2004 CLINICAL CANCER RESEARCH 10 (24): 8351-8356 Thomas GV; Horvath S; Smith BL; Crosby K; Lebel LA; et al. Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer	0	0
42	2	30	42 2004 CLINICAL CANCER RESEARCH 10 (24): 8594-8602 Schiff BA; McMurphy AB; Jasser SA; Younes MN; Doan D; et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer	1	4
43	2	38	43 2004 CLINICAL CANCER RESEARCH 10 (24): 8613-8619 Onn A; Isobe T; Wu WJ; Itasaka S; Shintani T; et al. Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer	0	0
44	2	77	44 2004 CURRENT OPINION IN CELL BIOLOGY 16 (6): 670-678 Senderowicz AM Targeting cell cycle and apoptosis for the treatment of human malignancies	0	3
45	2	78	45 2004 CURRENT OPINION IN CHEMICAL BIOLOGY 8 (4): 432-441 Mazitschek R; Giannis A Inhibitors of angiogenesis and cancer-related receptor tyrosine kinases	1	4
46	2	31	46 2004 CURRENT OPINION IN ONCOLOGY 16 (6): 536-541 Loi S; Buyse M; Sotiriou C; Cardoso F Challenges in breast cancer clinical trial design in the postgenomic era	0	0
47	2	46	47 2004 CURRENT OPINION IN UROLOGY 14 (5): 295-300 Highshaw RA; McConkey DJ; Dinney CP Integrating basic science and clinical research in bladder cancer: update from the first bladder Specialized Program of Research Excellence (SPORE)	0	2
48	2	85	48 2004 DRUG DEVELOPMENT RESEARCH 62 (2): 86-96 Hakonarsson H; Stefansson K Role of pharmacogenomics in drug development	0	2
49	2	79	49 2004 DRUG DISCOVERY TODAY 9 (14): 610-618 Savage SA; Chanock SJ Using germ-line genetic variation to investigate and treat cancer	0	1
50	2	56	50 2004 DRUG DISCOVERY TODAY 9 (18): 795-802 Desany B; Zhang ZM Bioinformatics and cancer target discovery	0	1
#	LCR	NCR	Node / Date / Journal / Author	LCS	GCS
51	2	84	51 2004 DRUG RESISTANCE UPDATES 7 (4-5): 245-255 Alaoui-Jamali MA; Dupre I; Qiang H Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling	0	1
52	5	88	52 2004 DRUGS 64 (21): 2475-2492 Frampton JE; Easthope SE Gefitinib - A review of its use in the management of advanced non-small-cell lung cancer	1	5
53	2	244	53 2004 ENDOCRINE-RELATED CANCER 11 (4): 659-687 Carter P; Smith L; Ryan M Identification and validation of cell surface antigens for antibody targeting in oncology	0	0
54	2	135	54 2004 ENDOCRINE-RELATED CANCER 11 (4): 689-708 Harari PM Epidermal growth factor receptor inhibition strategies in oncology	3	12
55	1	20	55 2004 EUROPEAN JOURNAL OF CANCER 40 (16): 2345-2348 Blackhall F; Thatcher N Chemotherapy for advanced lung cancer	0	1
56	2	152	56 2004 EUROPEAN JOURNAL OF PHARMACOLOGY 500 (1-3): 267-280 Nebert DW; Vesell ES Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead	2	13
57	1	17	57 2004 EUROPEAN UROLOGY 46 (6): 709-711 Clarke NW; Wylie JP Chemotherapy in hormone refractory prostate cancer: Where do we stand?	0	1
58	2	92	58 2004 EXPERT OPINION ON PHARMACOTHERAPY 5 (7): 1621-1633 Humblet Y Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours	1	2
59	1	108	59 2004 EXPERT OPINION ON THERAPEUTIC TARGETS 8 (6): 527-536 Hedley BD; Winquist E; Chambers AF Therapeutic targets for antimetastatic therapy	0	2
60	1	61	60 2004 EXPERT REVIEW OF PROTEOMICS 1 (3): 343-354 Chen WG; White FM Proteomic analysis of cellular signaling	0	1
#	LCR	NCR	Node / Date / Journal / Author	LCS	GCS
61	3	34	61 2004 HUMAN MOLECULAR GENETICS 13 (24): 3029-3043 Kakiuchi S; Daigo Y; Ishikawa N; Furukawa C; Tsunoda T; et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)	1	5
62	1	56	62 2004 INTERNATIONAL JOURNAL OF CLINICAL PRACTICE 58 (10): 970-976 Ng M; Cunningham D Cetuximab (Erbitux) - an emerging targeted therapy for epidermal growth factor receptor-expressing tumours	2	2
63	1	20	63 2004 JOURNAL OF CHEMOTHERAPY 16: 55-58 Casali PG; Bertulli R; Fumagalli E; Coco P; Grosso F; et al. Some lessons learned from imatinib mesylate clinical development in gastrointestinal stromal tumors	0	0
64	2	22	64 2004 JOURNAL OF CLINICAL ONCOLOGY 22 (16): 3209-3211 Dubinett SM; Elashoff D; Meyerson M Assessing prognosis in non-small-cell lung cancer: Avenues to a more complete picture?	0	0
65	2	44	65 2004 JOURNAL OF CLINICAL ONCOLOGY 22 (16): 3238-3247 Perez-Soler R; Chachoua A; Hammond LA; Rowinsky EK; Huberman M; et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer	45	57
66	1	4	66 2004 JOURNAL OF CLINICAL ONCOLOGY 22 (17): 3441-3442 Williams G Cancer drug development: For populations or for individuals?	0	0
67	2	19	67 2004 JOURNAL OF CLINICAL ONCOLOGY 22 (22): 4442-4445 Ratain MJ; Eckhardt SG Phase II studies of modern drugs directed against new targets: If you are fazed, too, then resist RECIST	1	2
68	2	42	68 2004 JOURNAL OF CLINICAL ONCOLOGY 22 (23): 4725-4729 Shuch B; Mikhail M; Satagopan J; Lee P; Yee H; et al. Racial disparity of epidermal growth factor receptor expression in prostate cancer	1	2
69	1	14	69 2004 JOURNAL OF INVESTIGATIVE DERMATOLOGY 123 (6): XI-XIII Grossman D Imatinib mesylate for melanoma: Will a new target be revealed?	0	0
70	1	10	70 2004 JOURNAL OF THE NATIONAL CANCER INSTITUTE 96 (13): 977-978 Korn EL Nontoxicity endpoints in phase I trial designs for targeted, non-cytotoxic agents	2	4
#	LCR	NCR	Node / Date / Journal / Author	LCS	GCS
71	3	19	71 2004 JOURNAL OF THE NATIONAL CANCER INSTITUTE 96 (15): 1117-1119 Pao W; Miller VA; Venkatraman E; Kris MG Predicting sensitivity of non-small-cell lung cancer to gefitinib: Is there a role for P-akt?	6	9
72	2	49	72 2004 JOURNAL OF THE NATIONAL CANCER INSTITUTE 96 (15): 1133-1141 Cappuzzo F; Magrini E; Ceresoli GL; Bartolini S; Rossi E; et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer	43	63
73	2	12	73 2004 M S-MEDECINE SCIENCES 20 (8-9): 750-751 Besse B; Le Chevalier T; Soria JC Selection of patients responsive to lressa((R))	0	0
74	1	33	74 2004 MOLECULAR CANCER THERAPEUTICS 3 (10): 1329-1334 Mikawa M; Wang H; Guo LL; Liu RW; Marik J; et al. Novel peptide ligands for integrin alpha(4)beta(1) overexpressed in cancer cells	0	1
75	2	74	75 2004 MOLECULAR CANCER THERAPEUTICS 3 (10): 1335-1342 Britten CD Targeting ErbB receptor signaling: A pan-ErbB approach to cancer	5	5
76	2	7	76 2004 NATURE 430 (6995): 30-30 Stratton MR; Futreal PA Cancer - Understanding the target	2	3
77	2	8	77 2004 NATURE 431 (7008): 525-526 Stephens P; Hunter C; Bignell G; Edkins S; Davies H; et al. Intragenic ERBB2 kinase mutations in tumours	45	53
78	2	11	78 2004 NATURE BIOTECHNOLOGY 22 (10): 1215-1217 Hood L; Perlmutter RM The impact of systems approaches on biological problems in drug discovery	1	10
79	1	105	79 2004 NATURE GENETICS 36 (11): S34-S42 Tate SK; Goldstein DB Will tomorrow's medicines work for everyone?	0	15
80	2	2	80 2004 NATURE MEDICINE 10 (8): 764-764 Katsnelson A Experts call for smarter approach to targeted therapies	0	1
#	LCR	NCR	Node / Date / Journal / Author	LCS	GCS
81	2	118	81 2004 NATURE MEDICINE 10 (8): 789-799 Vogelstein B; Kinzler KW Cancer genes and the pathways they control	11	118
82	3	26	82 2004 NATURE MEDICINE 10 (12): 1289-1291 Evans BJ; Flockhart DA; Meslin EM Creating incentives for genomic research to improve targeting of therapies	0	0
83	2	85	83 2004 NATURE REVIEWS CANCER 4 (9): 718-727 Dibb NJ; Dilworth SM; Mol CD Opinion - Switching on kinases: oncogenic activation of BRAF and the PDGFR family	6	16
84	4	88	84 2004 NATURE REVIEWS CANCER 4 (12): 956-965 Herbst RS; Fukuoka M; Baselga J Timeline - Gefitinib - a novel targeted approach to treating cancer	10	18
85	1	3	85 2004 NATURE REVIEWS DRUG DISCOVERY 3 (7): 547-U7 Farmer G Targeted lung cancer therapies	0	1
86	2	71	86 2004 NATURE REVIEWS DRUG DISCOVERY 3 (9): 739-748 Weinshilboum R; Wang LW Pharmacogenomics: Bench to bedside	1	15
87	2	84	87 2004 NATURE REVIEWS DRUG DISCOVERY 3 (9): 749-761 Koch WH Technology platforms for pharmacogenomic diagnostic assays	1	8
88	2	10	88 2004 NATURE REVIEWS DRUG DISCOVERY 3 (9): 763-769 Lesko LJ; Woodcock J Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective	5	18
89	4	92	89 2004 NATURE REVIEWS DRUG DISCOVERY 3 (12): 1001-1010 Daub H; Specht K; Ullrich A Strategies to overcome resistance to targeted protein kinase inhibitors	7	24
90	3	118	90 2004 NATURE REVIEWS DRUG DISCOVERY 3 (12): 1011-1022 Yingling JM; Blanchard KL; Sawyer JS Development of TGF-beta signalling inhibitors for cancer therapy	0	13
#	LCR	NCR	Node / Date / Journal / Author	LCS	GCS
91	2	65	91 2004 NATURE REVIEWS GENETICS 5 (9): 645-656 Roses AD Pharmacogenetics and drug development: The path to safer and more effective drugs	2	21
92	1	63	92 2004 NATURE REVIEWS GENETICS 5 (9): 669-676 Meyer UA Pharmacogenetics - five decades of therapeutic lessons from genetic diversity	1	14
93	2	101	93 2004 NATURE REVIEWS NEUROSCIENCE 5 (10): 782-792 Mischel PS; Cloughesy TF; Nelson SF DNA-microarray analysis of brain cancer: Molecular classification for therapy	1	11
94	0	29	94 2004 NEW ENGLAND JOURNAL OF MEDICINE 350 (21): 2129-2139 Lynch TJ; Bell DW; Sordella R; Gurubhagavatula S; Okimoto RA; et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib	628	629
95	1	10	95 2004 NEW ENGLAND JOURNAL OF MEDICINE 350 (21): 2191-2193 Green MR Targeting targeted therapy	14	18
96	1	40	96 2004 NEW ENGLAND JOURNAL OF MEDICINE 351 (4): 337-345 Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer	54	200
97	2	14	97 2004 NEW ENGLAND JOURNAL OF MEDICINE 351 (4): 391-392 Erlichman C; Sargent DJ New treatment options for colorectal cancer	2	7
98	2	14	98 2004 NEW ENGLAND JOURNAL OF MEDICINE 351 (5): 501-505 Roberts TG; Chabner BA Sounding board: Beyond fast track for drug approvals	2	3
99	1	41	99 2004 NEW ENGLAND JOURNAL OF MEDICINE 351 (8): 809-817 Temel J; Aquino SL; Lynch TJ; Wright CD; Mark EJ; et al. Case 26-2004: A 56-year-old woman with cough and a lung nodule - Large-cell undifferentiated carcinoma of the lung, stage IIIA (T1N2M0)	0	0
100	1	2	100 2004 NEW ENGLAND JOURNAL OF MEDICINE 351 (12): 1260-1260 Sorscher SM EGFR mutations and sensitivity to gefitinib	0	1

Page 1 of 7: [  1  2  3  4  5  6  7 ]
Generated by: HistCite 2005.08.29